**DaVita Inc. (DVA)** has experienced a substantial increase of over **70% in 2026**, fueled by consecutive positive earnings reports. The company, specializing in kidney disease treatment, is projected to **double its earnings** from **$8.38 per share in 2023** to **$18.37 per share by 2027**. On May 5, DaVita surpassed Q1 earnings estimates by **19%**, leading it to reach new all-time highs.
As of now, DaVita operates approximately **3,200 outpatient dialysis centers**, with roughly **82%** located in the U.S., serving about **300,000 patients**. The company holds nearly a **38% market share** in the U.S. dialysis market, which is anticipated to grow due to increasing rates of chronic kidney disease, affecting **1 in 10 adults in the U.S.** according to the CDC. This rise is primarily attributed to diabetes and high blood pressure.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
